Thrombocytosis as a prognostic factor in endometrial carcinoma
Thrombocytosis as a prognostic factor in endometrial carcinoma
复制标题
DOI：
10.1006/gyno.1998.5078
复制
发表时间：
1998-08-01
影响因子：
4.7
通讯作者：
Winter, R
中科院分区：
文献类型：
--
作者：
Gucer, F;Moser, F;Winter, R
我们回顾了血小板增多症（血小板计数大于或等于400，000/μ L）的患病率及其与135例连续子宫内膜癌患者预后的关系，并将血小板计数与其他预后因素进行了比较。135例患者中有19例（14%）有血小板增多症。血小板增多症在晚期疾病（II-IV期）、不良分级（G2和G3）、子宫深部肌层浸润和淋巴管间隙浸润中更常见。总的5年生存率为92%。19例有血小板增多症患者的5年生存率明显低于无血小板增多症患者（61%比96%，P < 0.0001）。血小板增多症患者的复发率明显高于血小板计数
We reviewed the prevalence of thrombocytosis (platelet count greater than or equal to 400,000/mu L) and its association with outcome in 135 consecutive endometrial carcinoma patients and compared the platelet count with other prognostic factors. Nineteen of 135 patients (14%) had thrombocytosis. Thrombocytosis was significantly more frequent in advanced disease (stage II-IV), unfavorable grade (G2 and G3), deep myometrial invasion, and lymph-vascular space invasion. The overall 5-year survival rate was 92%. The 5-year survival rate of the 19 patients with thrombocytosis was significantly worse than that of the patients without thrombocytosis (61 vs 96%, P < 0.0001). The recurrence rate was significantly higher in patients with thrombocytosis than in those with a platelet count